Astellas Accused Of Delaying Generic Drug Approval

Law360, New York (September 14, 2011, 9:50 PM EDT) -- Astellas Pharma US Inc. was hit with a putative class action by a union benefit fund Wednesday in Massachusetts federal court for allegedly keeping a generic version of its immune-suppressing drug off the market and jacking up indirect purchasers' costs.

The New Mexico United Food and Commercial Workers Union's and Employers' Health and Welfare Trust Fund said Astellas has abused the generic drug application system to keep a cheaper rival of its Prograf drug from getting approved. The fund cited Astellas' September 2007 citizen petition to...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.